Mirae Asset Launches New 'TIGER Global Obesity Treatment TOP2Plus ETF'

Mirae Asset Global Investments announced on the 29th that it will newly list the ‘TIGER Global Obesity Treatment TOP2Plus ETF’ on the Korea Exchange.

The ‘TIGER Global Obesity Treatment TOP2Plus ETF’ focuses its investment on Eli Lilly and Novo Nordisk, which account for about 80% of the global obesity treatment market. Eli Lilly, a manufacturer of obesity injection drugs, is currently the largest company by market capitalization in the global healthcare sector. Danish pharmaceutical company Novo Nordisk developed obesity treatments that have sparked a global craze, becoming the leading stock in Europe. As of the 28th, the investment proportions of Eli Lilly (28%) and Novo Nordisk (28%) in the ‘TIGER Global Obesity Treatment TOP2Plus ETF’ total over 50%.

Obesity treatment has emerged as a new innovative theme in the global healthcare market, with the number of obese patients worldwide estimated to exceed 1 billion. Although it temporarily slowed during the COVID-19 pandemic, it is expected to grow rapidly, centered on “Big Pharma” companies.

The ‘TIGER Global Obesity Treatment TOP2Plus ETF’ invests in a total of 10 global listed companies related to the obesity treatment theme, including representatives of Big Pharma such as Eli Lilly and Novo Nordisk, as well as AstraZeneca, Merck, Amgen, Roche, and Pfizer, which generate sales or are conducting R&D in obesity treatments. It is characterized by having abundant cash flow for new drug development. Among the 10 stocks, 9 were ranked among the top 20 global pharmaceutical companies in R&D expenses in 2022.

Cash holdings have also increased due to strong sales of COVID-19 vaccines and treatments. Utilizing abundant free cash flow as a dividend resource, the ‘TIGER Global Obesity Treatment TOP2Plus ETF’ pays monthly distributions.

To commemorate the launch of the ‘TIGER Global Obesity Treatment TOP2Plus ETF,’ Mirae Asset Global Investments is holding a listing celebration event for trading customers. Customers who meet the daily trading conditions for this ETF at Eugene Investment & Securities and Daishin Securities will receive cultural gift certificates through a lottery and other means. Detailed event information can be found on each securities firm’s website.

Song Min-gyu, head of the FICC ETF Management Department at Mirae Asset Global Investments, said, "In the obesity treatment industry, it is important to invest in Eli Lilly and Novo Nordisk, which lead the market, as well as Big Pharma companies with enormous financial power that are likely to be future winners." He added, "Through the TIGER Global Obesity Treatment TOP2Plus ETF, investors can receive monthly dividends while investing in the obesity treatment industry, a new innovative theme in the global healthcare market."

This content was produced with the assistance of AI translation services.